Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 3/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007114 | 0.83 | MAPT (0.40) | MAPT | |
| SCHEMBL12774199 | 0.82 | CHRM1 (0.36) | CHRM3CHRM4CHRM5CHRM1ALDH1A1 | |
| SCHEMBL14759114 | 0.81 | EPHX1 (0.36) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8336494 | 0.79 | ALDH1A1 (0.45) | CHRM3CHRM4CHRM5CHRM1ALDH1A1 | |
| SCHEMBL14759093 | 0.79 | EPHX1 (0.39) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL22954499 | 0.79 | ALDH1A1 (0.42) | CHRM3CHRM4CHRM5CHRM1ALDH1A1 | |
| SCHEMBL3040925 | 0.78 | SMYD3 (0.33) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3040923 | 0.78 | SMYD3 (0.33) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12049806 | 0.78 | ALDH1A1 (0.41) | CHRM3CHRM4CHRM5CHRM1ALDH1A1 | |
| SCHEMBL8912151 | 0.77 | ITGB3 (0.46) | ALDH1A1MAPTRAB9ASMN1; SMN2SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | CHRM3 3958/4885CHRM4 4560/4885CHRM5 2913/4885 |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | NR3C2, REN, CYP21A2 | CHRM3 3762/4885CHRM4 4367/4885CHRM5 2732/4885 |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | CHRM3 3958/4885CHRM4 4560/4885CHRM5 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.